Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.67 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.67 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.67 |
| ▸ | CES2 | O00748 | 1/20 | 0.48 |
| ▸ | CES1 | P23141 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MITF | O75030 | 1/20 | 0.41 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.41 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 2-Picolinic Acid SCHEMBL28200515 | 0.91 | LMNA (0.56) | LMNAL3MBTL1NAPRTP4HTMCES2 | |
| SCHEMBL917284 | 0.85 | CES2 (0.47) | LMNAL3MBTL1NAPRTP4HTMCES2 | |
| 2-Picolinic Acid SCHEMBL28737810 | 0.82 | LMNA (1.00) | LMNAL3MBTL1NAPRTP4HTMCES2 | |
| 2-Picolinic Acid SCHEMBL29368665 | 0.82 | — | — | |
| 2-Picolinic Acid SCHEMBL36055 | 0.82 | — | — | |
| 2-Picolinic Acid SCHEMBL7457912 | 0.82 | LMNA (1.00) | LMNAL3MBTL1NAPRTP4HTMCES2 | |
| 2-Picolinic Acid SCHEMBL674837 | 0.82 | LMNA (1.00) | LMNAL3MBTL1NAPRTP4HTMCES2 | |
| 2-Picolinic Acid SCHEMBL673571 | 0.80 | LMNA (0.95) | LMNAL3MBTL1NAPRTP4HTMCES2 | |
| 2-Picolinic Acid SCHEMBL3843691 | 0.80 | LMNA (0.95) | LMNAL3MBTL1NAPRTP4HTMCES2 | |
| 2-Picolinic Acid SCHEMBL15401824 | 0.80 | LMNA (0.95) | LMNAL3MBTL1NAPRTP4HTMCES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119119037-A | Cycloalkyl substituted triazolopyridine amide compound and preparation method and application thereof | 贵州大学 | 2024-12-13 | — | — | CN | disclosed |
| CN-107759564-A | Triazole pyridinecarboxylic glycine compounds, its method and medical usage | 中国药科大学 | 2018-03-06 | — | — | CN | disclosed |
| US-20100190801-A1 | TRIAZOLOPYRIDINE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES | SANOFI-AVENTIS (FR) | 2010-07-29 | — | — | US | disclosed |
| US-7718669-B2 | Triazolopyridine derivatives as inhibitors of lipases and phospholipases | SANOFI-AVENTIS (FR) | 2010-05-18 | — | — | US | disclosed |
| EP-1828184-B1 | [1,2,4]TRIAZOLO[4,3-A]PYRIDINE DERIVATIVES FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | MERCK SERONO SA (CH) | 2009-09-16 | — | — | EP | disclosed |
| US-20090030011-A1 | TRIAZOLOPYRIDINE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES | SANOFI-AVENTIS (FR) | 2009-01-29 | — | — | US | disclosed |
| CN-101291932-A | Triazolopyridine derivatives as inhibitors of lipases and phospholipases | SANOFI AVENTIS (FR) | 2008-10-22 | — | — | CN | disclosed |
| US-20070299103-A1 | [1,2,4]Triazolo[4,3-A]Pyridine Derivatives for the Treatment of Hyperproliferative Diseases | MERCK SERONO SA (CH) | 2007-12-27 | — | — | US | disclosed |
| EP-1828184-A1 | [1,2,4]TRIAZOLO[4,3-A]PYRIDINE DERIVATIVES FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | LABORATOIRES SERONO S.A. (CH) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006058752-A1 | [1,2,4]TRIAZOLO[4,3-A]PYRIDINE DERIVATIVES FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | LABORATOIRES SERONO S.A. (CH) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299103-A1 | [1,2,4]Triazolo[4,3-A]Pyridine Derivatives for the Treatment of Hyperproliferative Diseases | CDK4, CDK3, BRAF | LMNA 1862/4885L3MBTL1 1312/4885NAPRT 2084/4885 |
| US-20100190801-A1 | TRIAZOLOPYRIDINE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES | PNLIP, LIPC, LPL | LMNA 2158/4885L3MBTL1 3868/4885NAPRT 1536/4885 |
| US-20090030011-A1 | TRIAZOLOPYRIDINE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES | PNLIP, LIPC, LPL | LMNA 2158/4885L3MBTL1 3868/4885NAPRT 1536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.